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Introduction
In most studies long term survival in differentiated thyro-
id carcinoma (DTC) is excellent, especially in patients
under 40-50 years of age [1, 2, 3]. Patients under 45 years
of age are defined as a low risk group risk by TNM classi-
fication [4, 5]. Yet, the age range of this group is very wi-
de and encompasses children as well as patients in their
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I n t r o d u c t i o n. Standard therapy of differentiated thyroid cancer (DTC) comprises thyroid surgery, radioiodine treatment
and L-thyroxine suppressive treatment. However, in the case of young patients the extent of surgery and the need for radioio-
dine treatment are questioned by some authors on the basis of the overall good prognosis in this group.
A i m.  The aim of the study was to perform a retrospective analysis of prognostic factors for differentiated thyroid cancer in pa-
tients  in the first three decades of their life.
M a t e r i a l  a n d  m e t h o d s.  The study included 274 patients who were younger than 28 years at the day ofdiagnosis of DTC
and were observed for a mean time of 5 years. Uni- and multivariate analysis of prognostic factors for disease –  free survival
was performed with Cox's regression method.
Re s u l t s .  The actuarial survival rate was 100%, the 5 and 10-year actuarial disease free survival was 85% and 75%, respec-
tively. In a multivariate analysis lymph node metastases, the extent of surgery and radioiodine therapy were estimated as sta-
tistically significant, independent prognostic factors for DTC relapse.
C o n c l u s i o n s.  Radical treatment of DTC more advanced than pT1N0M0 should include total thyroidectomy and posto-
perative complementary radioiodine therapy. Such procedure is also justified in young patients, as it ensures a decrease of the
risk of recurrence.
Czynniki prognostyczne w przebiegu zró˝nicowanego raka tarczycy u m∏odych osób
C e l.  Leczenie operacyjne z nast´powym leczeniem radiojodem i stosowaniem supresyjnych dawek hormonów tarczycy ma
ustalone miejsce w leczeniu zró˝nicowanego raka tarczycy (ZRT). Jednak zakres operacji jak i wskazania do leczenia radio-
jodem wcià˝ wzbudzajà wiele kontrowersji, zw∏aszcza u m∏odych osób, u których rokowanie w przebiegu ZRT jest szczegól-
nie dobre.
W pracy przeprowadziliÊmy retrospektywnà analiz´ czynników prognostycznych wp∏ywajàcych na przebieg ZRT, rozpoznane-
go w pierwszych trzech dekadach ˝ycia.
M a t e r i a ∏  i m e t o d y k a.  Analiz´ przeprowadzono wÊród 274 chorych, u których zró˝nicowanego raka tarczycy rozpozna-
no przed ukoƒczeniem 28 roku ˝ycia. Âredni czas obserwacji wynosi∏ 5 lat. Wp∏yw czynników prognostycznych na prze˝ycie bez-
objawowe oceniano jedno- i wielowariantowà analizà regresji wed∏ug Cox'a.
W y n i k i.  W ca∏ej grupie chorych prze˝ycie ca∏kowite wynosi∏o 100%, a prze˝ycie bezobjawowe po 5 i 10 latach obserwacji od-
powiednio 85% i 75%. W analizie wielowariantowej zawansowanie choroby nowotworowej, zakres zabiegu operacyjnego oraz
leczenie radiojodem mia∏y istotny wp∏yw na prze˝ycie bez objawów nawrotu choroby.
W n i o s k i . Radykalne leczenie ZRT, w stopniu zaawansowania innym ni˝ p T1N0M0, powinno obejmowaç ca∏kowite usu-
ni´cie gruczo∏u tarczowego z nast´powym leczeniem radiojodem. Dotyczy to równie˝ m∏odych osób, u których post´powanie
takie w sposób istotny zmniejsza ryzyko nawrotu choroby nowotworowej.
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forties. In the recent years many controversies arose and
some authors claim that DTC in children tends to be mo-
re aggressive than in adults [2].
Only about 3 – 10% of all thyroid carcinomas occur
in patients younger than 20 years of age [6, 7]. Since the
first report of thyroid cancer in a child in 1902, for the first
several decades thyroid carcinoma in children was regar-
ded as a medical curiosity. A rapid increase in the number
of children with thyroid cancer observed in the 1960's was
related to the previous exposure of the neck region to
ionisation irradiation, mostly applied as the treatment of
various benign diseases [8, 9]. A very distinct increase in
prevalence of thyroid cancer among European children
has surfaced in Belarus, Ukraine and Russia after the
Chernobyl nuclear accident [10-12]. The peak of post-
-Chernobyl incidence of DTC moves now towards adole-
scence and the first years of adulthood. No similar rise has
been observed in Poland. However a steady rise in the
prevalence of thyroid carcinoma has been observed, be-
ginning with the 1980's [13]. Thus the number of the new
cases has increased from 200-300 to more than 1000 per
year. The fact of increasing prevalence of thyroid cancer
in young patients underscores the importance of defining
the adverse prognostic factors and the appropriate treat-
ment for this group of patients. The low incidence of the
disease, its protracted course and the need for a long pe-
riod of follow up to establish risk factors, make prospec-
tive studies difficult to perform. Thus, the best possible
way seems to be a uni- and multivariate regression analy-
sis of retrospective data in a homogenous population.
Material and methods
P a t i e n t s
Medical records from 274 patients treated for differentiated
thyroid cancer between 1972 and 1995 were reviewed retrospec-
tively (Tab. I). There were 109 children (group I) and 165 adults
(group II) less than 28 years of age at the diagnosis of DTC.
This age limit was chosen to cover all patients who were younger
than 18 years in May 1986, during the Chernobyl-induced conta-
mination. The follow-up time ranged between 1 and 23 years; an
average of 5 years in group I and 3.5 years in group II. Seven
children and 37 young adults had thyroid cancer diagnosed shor-
tly before the time of analysis and they were all excluded from
the study. The results obtained for children were also a subject of
a separately published analysis [14].
S u r g e r y
Standard treatment of DTC applied at our centre was total thy-
roidectomy followed by radioiodine therapy. Primary total thyro-
idectomy was performed using an extracapsular approach
[15,16]. Resection of the central lymph-node compartment and
bilateral biopsy of lateral neck lymph nodes were performed
routinely. If the latter was positive, it was followed by radical mo-
dified neck dissection on the affected side. The cervical vein
and sternocleido-mastoid muscle were preserved.
Many patients were operated in other centres, 86 of them
underwent sub-total surgery. We assessed the radicality of pre-
vious thyroid surgery by ultrasound and 131I scan performed
after 4 weeks of thyroxine withdrawal. In patients with thyroid
remnants larger than 1 ml by ultrasound on either side of the
neck or showing significant 131I neck uptake, secondary radical
thyroidectomy was performed.
In those cases where surgery had been carried out in other
centres lymph node biopsy was not always performed and in so-
me cases only lymph node excision was applied. In those cases ra-
dical lymphadenectomy was performed only when enlarged
lymph nodes were detected by clinical or ultrasound examination.
Ultimately, radical thyroid surgery was administered to
188 (68.6%) patients: 81 children and 107 young adults. There
were no differences in the extent of thyroid operation with refe-
rence to the lymph nodes status (Tab. II).
Tab. II. Extent of thyroid surgery in relation to lymph node status
Lymph nodes Extent of operation p
total less than total
N0 Group I 37 (86%) 6 (14%) ns
Group II 58 (83%) 12 (17%)
N1 Group I 44 (75%) 15 (25%) ns
Group II 49 (84%) 9 (16%)
H i s t o p a t h o l o g y  a n d  s t a g i n g
On the basis of postoperative histopathologic examination 165
(60%) tumours were classified as papillary carcinoma and 109
(40%) as follicular carcinoma (Tab. I). Every diagnosis was re-
-evaluated by another pathologist from the Department of Tu-
mour Pathology in our Institute according to the WHO 1986
classification.
All patients were diagnosed with a palpable neck mass be-
fore operation. The exact tumour diameter (T stage) was not al-
ways reported, thus in Table I we reported only the prevalence of
lymph node and distant metastases.
Lymph node metastases were diagnosed in 128 (46%) pa-
tients. 24 (8.8%) patients suffered from distant metastases, lung
metastases were prevalent (Tab. III). In 12 patients lung metasta-
ses were recognised on the basis of positive whole body 131I scan
(WBS) but negative chest x-rays – in those cases micronodular
lung dissemination was diagnosed. In all but one patient the di-
stant metastases were functional and could be observed on
131I whole body scan.
C o m p l e m e n t a r y  t r e a t m e n t
Patients with radioiodine uptake >1% in thyroid bed and/or in
lymphonodal localisation or with distant metastases were given
postoperative radioiodine treatment. Fixed 131I doses (mostly
60 or 100 mCi) were applied. 157 patients were treated to abla-
te thyroid remnants or to treat remnants after surgery of lymph
node metastases. In another 16 (6%) patients the first radioiodi-
ne treatment was applied to treat distant metastases together
Tab. 1. Characteristics of the studied groups
Children Young adults all patients p
6-17 years 18-27 years 19.3 /age
mean 13.6 mean 23,2
gender female 76 (69%) 137 (83%) 213 0.012
male 33 (31%) 28 (17%) 61
Histo- papillary 77 (71%) 88 (54%) 165 0.096
pathology follicular 32 (29%) 77 (46%) 109
lymph node metastases 64 (59%) 64 (39%) 128 0.037
distant metastases 17 (16%) 7 (4%) 24 0.006
total thyroidectomy 81 (79%) 107 (83%) 188 ns
radioiodine treatment 70 (69%) 103 (80%) 173 0.038
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with thyroid or lymph node remnants. TSH suppressive therapy
with L-thyroxine was introduced in all patients.
F o l l o w - u p
After treatment all patients underwent regular follow – up.
When radioiodine therapy was given for ablation of thyroid
remnants and no distant metastases were detected on the post-
herapeutic whole body scintigraphy, remission was evaluated at
a check-up carried out six months after 131I treatment. The
check-up consisted of clinical evaluation, neck ultrasound, chest
X ray, thyroglobulin (Tg) estimation and 131I whole body scinti-
graphy (WBS) performed after 4 weeks of thyroxine withdrawal.
When the results of these examinations were negative, the pa-
tients were followed-up regularly at six month intervals (after 5
years at 12 month intervals) while on thyroxine suppressive the-
rapy. Clinical examination, TSH and Tg estimations were perfor-
med each time, and neck ultrasound and chest X-ray at annual
intervals. 131I WBS and Tg estimations during endogenous TSH
stimulation were routinely performed after 2 and 5 years and
then at 5 year intervals.
In patients treated with 131I therapy for lymph node or di-
stant metastases, the remission was evaluated at check-up carried
out six months after the last 131I therapy. Radioiodine therapy
was discontinued when no foci of 131I uptake were observed on
posttherapeutic 131I WBS. The accumulated 131I activity ranged
between 60-580 mCi. When remission was achieved, the subse-
quent follow-up was carried out according to the scheme outli-
ned above.
Recurrences were recognised in 25 patients – 16 children
and 9 young adults (Tab. IV). In most cases locoregional relap-
ses were stated, in three patients with concurrent distant relap-
se. In nine patients the recurrence was detected at the follow up
after the primary treatment performed or evaluated in our cen-
tre. The other 16 (6% of all patients) were referred to our centre
only after the diagnosis of relapse.
M e t h o d s  f o r  e v a l u a t i o n  o f  d i s e a s e  s t a t u s
1. Ultrasound neck examination was performed with different
ultrasound equipment, which in all cases was supplied with
a 7.5 MHz linear head.
2. Diagnostic WBS was performed with 1-2 mCi of 131I. Until
1995 a rectilinear whole body scanner was used (Picker Nuc-
leograph). In 1995 a dual head γ camera with parallel high
energy collimators was introduced (Siemens, Multispect 2).
AP and PA projections were obtained with additional spot
projections of the neck area and the chest. TSH level was
evaluated simultaneously and was expected to exceed
25 mU/L. 24-hour neck uptake was measured by a scintilla-
tion probe (Scaler P21) or with region of interest (ROI)
technique. The cut-offs used were 1% and 0,4% respectively.
Posttherapeutic WBS was carried out on day 4 with a MB
9200 camera with reverse pinhole collimator until 1995 and
thereafter with the Multispect 2.
3. Thyroglobulin estimations have been done with immu-
nofluorometric Wallac Delfia kits on a routine basis since
1993. The functional sensivity of this assay is 1 ng/ml. Our
own cut-off values were estimated by ROC analysis at
a 95% specificity level [17]. During L-thyroxine therapy the
cut-off value was 4 ng/ml, off therapy 30 ng/ml. The recove-
ry of added Tg was routinely measured. Our own cut-off li-
mit for Tg recovery was 70% and serum thyroglobulin esti-
mations were evaluated as valid only when this condition
was met.
4. TSH examinations were performed with Abbot hTSH II
generation assay. A value of 0.05-0.3 IU/L was accepted
as evidence for suppression of endogenous TSH. Levels
above 25 IU/L were expected for endogenous TSH stimula-
tion.
Statistical analysis
Because there were no deaths, the end point of the analysis was
disease free-survival, defined as the period between the first
negative examination carried out after the primary treatment
(thyroidectomy or thyroidectomy followed by radioiodine) and
the last examination confirming the disease-free state. For relap-
sed patients, the end of the disease free period was the time of
detection of the recurrence. All local recurrences were confir-
med by histopathological examination. Distant relapses were
diagnosed on the basis of 131I whole body scintigraphy, increase
in serum Tg, X ray and/or computer tomography and, in rare ca-
ses, 99m Tc methylene diphosphonate scintigraphy.
Prognostic factors listed below were first studied separate-
ly using the Cox proportional hazard model in a single-step ana-
lysis and then the multiple regression model was obtained for
each combination of factors to compare their joined progno-
stic impact on DFS. P values <0.05 were considered statistical-
ly significant. Independent variables assessed for their influence
on disease free-survival included:
1. Patient-related factors
- age: 6-10/11-13/14-17/18-27,
- sex: female/male.
2. Tumour-related factors
- histopathology: papillary/follicular,
- lymph node metastases: present/not present.
3. Treatment-related factors
- extent of thyroidectomy – total/less than total,
- postoperative radioiodine treatment – applied/not applied.
Results
There were no deaths in the studied group. Actuarial di-
sease-free survival after 5 and 10 years of observation
was 85% and 75% respectively (Fig. 1).
The best prognosis was observed in the group of
young adults, where disease-free survival after 5 and 10
years was 90% and 87% respectively. Children had di-
stinctly less favourable prognosis in relation to disease-
Tab. III. The site of initial presentation and the outcome
of distant metastases
Site No WBS X-ray CR R
lung* Group I 14* 12 5 11 2
Group II 5 5 3 3 2
bone Group I 2 2 2 1 1
Group II 1 1 1 0 1
liver (1 child) 1 1 0 1 0
*one in one child parents did not give their consent on radioiodine dia-
gnostic examination or treatment
WBS – whole body scintigraphy
X-ray – X ray examination
CR – complete remission
R – partial remission
Tab. IV. Characteristics of the recurrences
site group I group II all p
distant 3 0 3 0.028
distant and local relapse 3 1 4 0.100
local relapse 10 8 18 0.092
all sites 16 9 25 0.003
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-free survival (p<0.05, Fig. 1). When they were subdivided
into age groups (Fig. 2) the difference between small
children (younger than 10 years of age) or young teena-
gers (11 to 13 years of age) and adults still remained signi-
ficant. Adolescents (14 to 17 years) who formed the most
numerous group did not show the significantly worse co-
urse of disease than young adults.
In univariate analysis gender and tumour histopatho-
logy did not correlate with the disease free-survival. Lymph
nodes metastases adversely affected disease free-survival in
the entire group of patients, but the difference was only of
borderline significance (p=0.056, Fig. 3). In children the
risk of recurrence did not differ between children with or
without lymph node metastases and in the young adults
group this was only of borderline significance.
A significant correlation was found between the the-
rapeutic approach and the rate of recurrences by univaria-
te comparison. Total thyroidectomy resulted in 91% DFS
after 10 years while a non-radical operation was connec-
ted with 41% and 60% risk of relapse after 5 and 10 years
respectively (Fig.3). When radical thyroidectomy was ap-
plied, there were no differences in disease free-survival
between children and young adults. However, in children
without radical surgery, disease free-survival was signifi-
cantly worse than in young adults.
The subsequent radioiodine treatment also signifi-
cantly influenced disease free-survival (Fig. 4). After 5
years of observation 94% of patients in the 131I tre-
ated group were disease free while 32% and 50% of
patients without radioiodine treatment relapsed after
5 and 10 years of observation. When treated with the same
treatment modality, there were no statistically significant
differences observed between children and young adults.
When multivariate analysis was applied, lymph node
status, extent of operation and radioiodine treatment had
statistically significant impact on disease free-survival
(Tab. V).
Lymph nodes metastases increased the risk of re-
lapse by a factor of 4. However, the impact was visible on-
ly when the entire group of patients under the age of 28
was analysed. In children the confidence interval was wi-
de and p-value was higher than 0,05.
The factors with favourable significance in the mul-
tivariate analysis were total thyroidectomy and radioiodi-
ne treatment (Tab. V). The risk of recurrence was 6 times
higher among patients operated with the less extensive ap-
proach and the difference was highly significant statistical-
ly. Postoperative radioiodine treatment independently
reduced the risk of recurrence by a factor of 5.
Discussion
Age is recognised as one of the most important prognostic
factors for disease free-survival in differentiated thyroid
Fig 1. Actuarial disease free survival in DTC patients younger 
then 28 years of age
Fig. 2. Disease free survival by age
Fig. 3. Disease free survival by lymph node metastases
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carcinoma. Patients younger than 45 years of age show
longer periods of survival and a lower incidence of re-
currence. Although children tend to be diagnosed at
a more advanced stage of the disease and have higher
recurrence rates [2, 18-20] the rate of survival seems to be
unaffected [2, 18]. This has caused many controversies
concerning the adequate therapeutic strategy in the cases
of DTC diagnosed in young patients.
In our study we analysed 274 patients with differen-
tiated thyroid cancer, who were younger than 28 years
of age at the time of disease diagnosis. Several factors
affecting the prognosis of DTC were evaluated first in
the entire group of patients and then compared with our
previous results [14] obtained for the children's group.
The patients were treated with 131I and followed in the sa-
me medical centre for a mean time of 5 years. To determi-
Fig. 4. Disease free survival by extent of operation
Fig. 5. Disease free survival by radioiodine treatment
Tab. V. Multivariate Cox regression analysis of prognostic factors
All patients younger Young adults Children
than 28 years of age
Factor Risk factor Risk factor Risk factor
p (90% confidence p (90% confidence p (90% confidence
interval) interval) interval)
Age at diagnosis
[years] 0.964 0.99 (0.92-1.0) 0.560 1.1 (0.82-1.4) 0.080 0.79 (0.63-0.99)
Gender
[female / male] 0.959 0.97 (0.38-2.4) 0.550 2.1 (0.26-1.4) 0.800 0.83 (0.26-2.6))
Histopathology
[papillary / follicular] 0.160 0.51 (0.23-1.1) 0.101 0.2 (0.06-1.0) 0.777 0.82 (0.27-2.5)
Lymph node metastases at DTC diagnosis
[present / not present] 0.027 3.1 (1.3-7.2) 0.020 9.0 (1.8-43) 0.373 1.8 (0.6-5.4
Extent of operation
[total / less than total] 0.0001 6.2 (2.8-13.7) 0.017 7.6 (1.8-31.1) 0.007 9.6 (2.3-39.1)
Radioiodine treatment
[yes / no] 0.001 5.8 (2.4-14.1) 0.014 7.4 (9.1-28.3) 0.073 5.1 (1.1-32.2)
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ne death rate, the follow up time should be, in a majority
of patients, longer then 5 years [21-24] and the observa-
tion of no cancer-related death in our study is only a pre-
liminary one. Therefore the importance of prognostic
factors was calculated in relation to disease free survival.
Disease-free survival was closely related to the pa-
tient's age and was the longest in young adults. Mazzaffe-
ri et al. [2] noted the highest rate of recurrences in pa-
tients younger than 10 or older then 60 years. Similarly,
the report from Children Cancer Study Group [25] and
other reports have claimed that the younger the child at
diagnosis the higher the rate of relapse. This was confir-
med in our study. Children in the youngest group, less
then 10 years of age, had the worst prognosis and all of
them relapsed. The difference was statistically significant
both when compared with adolescents 14 to 17 years of
age and young adults. However, multivariate analysis did
not prove any significant correlation between age at dia-
gnosis and disease-free survival. Instead it revealed extent
of surgery as the most potent prognostic factor for the
disease-free survival. Accordingly the effect of the latter
factor could have been stronger than the influence of age.
Children revealed more metastases than young
adults. For a long time the presence of lymph node meta-
stases at diagnosis was not considered a negative pro-
gnostic factor in DTC [26-31]. Recently, more and more
authors have claimed that local metastases adversely influ-
ence disease-free survival [1, 29, 32-34]. Mazaferri and
Jhang [2] showed an increased risk of relapse in young pa-
tients with lymph node metastases without any influence
on overall survival. Similar observations may be found
elsewhere [1, 35]. Some authors claim that along with
the presence of node metastases, their site, size, number
and extension beyond the capsule probably also exert
their impact on prognosis [34, 36]. However, these factors
were not taken into account in most series. Also in the
present study we analysed only the presence or absence of
lymph node metastases. Half of the lymphangiectomies
were performed at other institutions and more specific da-
ta was often lacking. The exact extent of lymph node dis-
section was not always stated as well. Even though our cri-
teria of lymph node status were very rough, patients with
lymph nodes metastases suffered from significantly worse
prognosis, but the difference was statistically significant
only in the entire group, but not in the subgroup of chil-
dren. We must stress that all but two children, and all
young adults with distant metastases suffered also from
neck metastases. This fact should also draw our atten-
tion to lymph node metastases as a possible adverse pro-
gnostic factor.
In our study we did not observe any correlation be-
tween histology or gender and prognosis of DTC. Ho-
wever in many papers such correlation has been suggested
[2, 19, 34, 35].
Considering treatment-related factors, our results
remain in strong opposition to authors opting for conse-
rvative surgery in young patients. Our rate of recurrence
was very distinctly related to the extent of surgery both in
the entire group of patients and in subgroups. The re-
sults of non- total thyroidectomies were much worse in
children than in adults (DFS 15% vs 75%, p<0.05).When
total thyroidectomy was performed, there were no diffe-
rences in DFS between children and young adults. This
observation supports the necessity for radical thyroid sur-
gery both in children and young adults.
Many authors are convinced that in children and
young adults (as in adults), total thyroidectomy is the
most adequate treatment for any DTC, with the exception
of unifocal papillary microcarcinoma [1, 2, 37]. Oppo-
nents of an extensive surgery in young patients cite the
low mortality rate in this age group [14, 26, 34, 40, 41].
They opt for a conservative surgical approach, despite
the high rate of recurrences in non-radically operated
patients. However, their studies can be biased by a se-
lection of patients with more extensive disease for treat-
ment with radical surgery. Robie et al [34] in their study
from 1998 advocated total or subtotal thyroidectomy on-
ly in patients with distant metastases, extensive lymph
node involvement, or invasive extracapsular tumours. On-
ly a year later they reanalysed the results in children with
thyroid carcinoma confined to the thyroid gland and sho-
wed that disease-free survival improved in patients treated
with total or subtotal thyroidectomy when compared with
lobectomy [42].
The therapeutic benefit of complementary treatment
with radioiodine for differentiated thyroid carcinoma was
clearly showed by Mazzaferri et al. [2, 43]. Also in our stu-
dy the favourable effect of radioiodine treatment was hi-
ghly significant, both in uni- and multivariate analysis.
These results are meaningful for two reasons. Firstly, ra-
dioiodine treatment was mainly given after total thyro-
idectomy, but despite that fact the independent effect of
131I therapy was still observable. Secondly, all postope-
rative 131I treatments were included in our analysis, inclu-
ding those performed in the presence of distant meta-
stases. The presence of radiological signs of lung metasta-
ses in 4 children and 3 young adults receiving 131I post
thyroidectomy hampered their prognosis in comparison to
the group of patients, who were not treated postoperati-
vely with radioiodine[2, 44]. Nevertheless, their disease-
-free survival increased in comparison to patients without
complementary 131I therapy. Both these facts speak in
favour of wide indications for 131I complementary thera-
py after radical surgery also in young patients. It is well
known that 131I treatment does not impair fertility or in-
duce inborn defects and it is not contraindicated in fema-
les in child bearing age [45, 46].
In conclusion, our observations show that treatment
of DTC in the first three decades of life should include to-
tal thyroidectomy and postoperative complementary ra-
dioiodine therapy in every case of thyroid carcinoma mo-
re advanced than pT1N0M0 papillary carcinoma.
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